| Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia C Weyer, T Funahashi, S Tanaka, K Hotta, Y Matsuzawa, RE Pratley, ... The Journal of Clinical Endocrinology & Metabolism 86 (5), 1930-1935, 2001 | 5163 | 2001 |
| Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects M Maffei, J Halaas, E Ravussin, RE Pratley, GH Lee, Y Zhang, H Fei, ... Nature medicine 1 (11), 1155-1161, 1995 | 4971 | 1995 |
| The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus C Weyer, C Bogardus, DM Mott, RE Pratley The Journal of clinical investigation 104 (6), 787-794, 1999 | 2736 | 1999 |
| Impaired fasting glucose and impaired glucose tolerance: implications for care DM Nathan, MB Davidson, RA DeFronzo, RJ Heine, RR Henry, R Pratley, ... Diabetes care 30 (3), 753-759, 2007 | 2154 | 2007 |
| Diabetes in older adults MS Kirkman, VJ Briscoe, N Clark, H Florez, LB Haas, JB Halter, ES Huang, ... Diabetes care 35 (12), 2650, 2012 | 1898 | 2012 |
| 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes—2023 NA ElSayed, G Aleppo, VR Aroda, RR Bannuru, FM Brown, D Bruemmer, ... Diabetes care 46 (Supplement_1), S19-S40, 2023 | 1428 | 2023 |
| Cardiovascular outcomes with ertugliflozin in type 2 diabetes CP Cannon, R Pratley, S Dagogo-Jack, J Mancuso, S Huyck, ... New England Journal of Medicine 383 (15), 1425-1435, 2020 | 1371 | 2020 |
| Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance C Weyer, JE Foley, C Bogardus, PA Tataranni, RE Pratley Diabetologia 43, 1498-1506, 2000 | 1036 | 2000 |
| High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes B Vozarova, N Stefan, RS Lindsay, A Saremi, RE Pratley, C Bogardus, ... diabetes 51 (6), 1889-1895, 2002 | 942 | 2002 |
| Circulating interleukin‐6 in relation to adiposity, insulin action, and insulin secretion B Vozarova, C Weyer, K Hanson, PA Tataranni, C Bogardus, RE Pratley Obesity research 9 (7), 414-417, 2001 | 925 | 2001 |
| Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis DK McGuire, WJ Shih, F Cosentino, B Charbonnel, DZI Cherney, ... JAMA cardiology 6 (2), 148-158, 2021 | 889 | 2021 |
| Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body … N Stefan, B Vozarova, T Funahashi, Y Matsuzawa, C Weyer, RS Lindsay, ... Diabetes 51 (6), 1884-1888, 2002 | 812 | 2002 |
| Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials N Sattar, MMY Lee, SL Kristensen, KRH Branch, S Del Prato, NS Khurmi, ... The lancet Diabetes & endocrinology 9 (10), 653-662, 2021 | 809 | 2021 |
| High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes B Vozarova, C Weyer, RS Lindsay, RE Pratley, C Bogardus, PA Tataranni Diabetes 51 (2), 455-461, 2002 | 773 | 2002 |
| Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial RE Pratley, M Nauck, T Bailey, E Montanya, R Cuddihy, S Filetti, ... The Lancet 375 (9724), 1447-1456, 2010 | 769 | 2010 |
| 6. Glycemic Targets: Standards of Care in Diabetes—2023 NA ElSayed, G Aleppo, VR Aroda, RR Bannuru, FM Brown, D Bruemmer, ... Diabetes care 46 (Supplement_1), S97-S110, 2023 | 730* | 2023 |
| Neuroanatomical correlates of hunger and satiation in humans using positron emission tomography PA Tataranni, JF Gautier, K Chen, A Uecker, D Bandy, AD Salbe, ... Proceedings of the National Academy of Sciences 96 (8), 4569-4574, 1999 | 722 | 1999 |
| 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes—2023 NA ElSayed, G Aleppo, VR Aroda, RR Bannuru, FM Brown, D Bruemmer, ... Diabetes care 46 (Suppl 1), S140, 2023 | 708 | 2023 |
| Efficacy and safety of degludec versus glargine in type 2 diabetes SP Marso, DK McGuire, B Zinman, NR Poulter, SS Emerson, TR Pieber, ... New England Journal of Medicine 377 (8), 723-732, 2017 | 706 | 2017 |
| Vitamin D supplementation and prevention of type 2 diabetes AG Pittas, B Dawson-Hughes, P Sheehan, JH Ware, WC Knowler, ... New England journal of medicine 381 (6), 520-530, 2019 | 694 | 2019 |
John B BuseUniversity of North Carolina在 med.unc.edu 的电子邮件经过验证
